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Abstract
With the advent of anti-vascular endothelial growth factor (VEGF) therapy, clinicians are now focused on
various treatment strategies to better control neovascular age-related macular degeneration (NVAMD), a
leading cause of irreversible blindness. Herein, we retrospectively reviewed consecutive patients with
treatment-naïve NVAMD initially classified based on fluorescein angiography (FA) alone or with an
anatomic classification utilizing both FA and optical coherence tomography (OCT) and correlated long-
term visual outcomes of these patients treated with an anti-VEGF Treat-and-Extend Regimen (TER) with
baseline characteristics including neovascular phenotype. Overall, 185 patients (210 eyes) were followed
over an average of 3.5 years (range 1–6.6) with a retention rate of 62.9%, and visual acuity significantly
improved with a TER that required a mean number of 8.3 (±1.6) (± standard deviation) intravitreal anti-
VEGF injections/year (range 4–13). The number of injections and the anatomic classification were
independent predictors of visual acuity at 6 months, 1, 2, 3 and 4 years. Patients with Type 1
neovascularization had better visual outcomes and received more injections than the other neovascular
subtypes. There were no serious adverse events. A TER provided sustained long-term visual gains. Eyes
with Type 1 neovascularization had better visual outcomes than those with other neovascular subtypes.
Keywords: anatomical classification, choroidal neovascularization, fluorescein angiography classification,
intravitreal anti-VEGF injections, neovascular age-related macular degeneration, Treat and Extend
Regimen
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1. Introduction
Age-related macular degeneration (AMD) is a leading cause of irreversible severe vision loss and
blindness in patients 50 and older [1]. Neovascular AMD is responsible for 80% of cases of severe vision
loss due to AMD [2]. Unprecedented visual gains were obtained with monthly intravitreal ranibizumab in
the pivotal randomized clinical trials [3,4] and led to a paradigm shift in the treatment of neovascular
AMD. However, monthly injections for the management of neovascular AMD patients seen in clinical
practice may be difficult to maintain for extended periods [5]. The favorable results predicted for pro re
nata (PRN) regimens by the results of clinical trials may not apply to what actually occurs in clinical
practice over long-term treatment due to the difficulty of maintaining monthly visits [6]. An alternative
individualized treatment strategy known as a Treat-and-Extend Regimen (TER) can reduce both the
number of injections as compared to fixed monthly therapy and office visits and ancillary testing as
compared to both fixed monthly and PRN regimen [7,8]. The TER has now become the regimen used most
frequently in the United States.
While the initial major clinical trials for anti-vascular endothelial growth factor (VEGF) therapy in
neovascular AMD did not include a TER [3,4,9,10], more recent studies have demonstrated the TER’s
ability to yield favorable visual acuity and safety results in patients treated for up to 1 [11,12], 2 [13,14,15]
and 3 years [7,16,17]. Moreover, a review of published studies comparing TER and PRN approaches in
patients with neovascular AMD [18,19] performed for a consensus manuscript on the TER found that TER
was associated with greater (and possibly earlier) visual improvement compared to PRN regimens [8]. The
value of the TER still needs validation in larger patient cohorts with long-term follow-up [8]. Therefore,
the first objective of this study was to determine if a TER can maintain long-term visual benefits in newly
diagnosed treatment-naive neovascular AMD patients treated by a single physician (K. Bailey Freund)
over a six-year time period.
The second objective of this study was to correlate baseline demographic and clinical factors with visual
changes and long-term visual outcomes. In order to refine the exploration for correlations between baseline
lesion composition with visual outcomes, neovascular lesion subtypes were graded using two different
classification schemes: the original fluorescein angiography (FA) classification system defined two
decades ago by the Macular Photocoagulation Study (MPS) [20] which continues to be used in all major
clinical trials and the anatomic classification based on multimodal imaging combining both fluorescein
angiography (FA) and optical coherence tomography (OCT). The anatomic classification which is based
upon Grossniklaus and Gass’ original observations from histopathology [21] has been described by Freund
and associates [22]. The clinical relevance of the anatomic classification in neovascular AMD has recently
been demonstrated in two reports analyzing the same cohort of patients studied in this manuscript [23,24].
Herein, we explore the clinical relevance of using the anatomic classification in neovascular AMD by
comparing the correlations between long-term visual outcome and neovascular subtypes graded with both
classification schemes.
2. Methods
This retrospective cohort study design (#20070317, 3 February 2015) was approved by the Western
Institutional Review Board (Olympia, WA, USA). It complied with the Health Insurance Portability and
Accountability Act of 1996 and followed the tenets of the Declaration of Helsinki.
2.1. Data Collection
We retrospectively reviewed the charts and imaging data for a consecutive series of 374 patients who
initiated intravitreal anti-VEGF therapy for newly diagnosed, treatment naïve neovascular AMD in one or
both eyes between 1 January 2006 and 1 December 2011 and had at least 47 weeks of follow-up by a
single physician (K. Bailey Freund) at two offices of the private practice of Vitreous Retina Macula
Consultants of New York, New York, NY, USA.
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Inclusion criteria were similar to the MARINA [3] and the ANCHOR [4] study groups. All participants
were older than 50 years with newly diagnosed treatment-naïve neovascular AMD, as evidenced by
clinical examination and FA. Baseline visual acuity (VA) (best recorded distance VA with spectacles,
manifest refraction, and/or pinholes) was 20/20 to 20/800 on a Snellen chart (differed from
ANCHOR/MARINA which included 20/40 to 20/320 on the Early Treatment Diabetic Retinopathy Study
charts). Additionally, eyes in this study must have had OCT imaging (time-domain or spectral-domain)
performed at the time of initial diagnosis.
Exclusion criteria were any of the following: previous treatments for choroidal neovascularization (CNV)
in the study eye including photodynamic therapy (PDT), intravitreal steroids, intravitreal pegaptanib, or
thermal laser; and eyes with CNV lesions with subfoveal fibrosis, central geographic atrophy (GA) at
baseline, retinal pigment epithelial tears, or composed of more than 50% hemorrhage. Eyes with CNV
secondary to other maculopathies including degenerative myopia, angioid streaks, presumed ocular
histoplasmosis syndrome, or inflammatory maculopathies were excluded.
Demographic information including age, gender, race, family history of AMD, smoking status (current,
former, never), history of hypertension and diabetes, history of statin, aspirin, clopidogrel, and/or warfarin
use, and history of glaucoma were collected for each patient. The number of anti-VEGF injections an eye
received, along with best-corrected visual acuity (Snellen) and intraocular pressure at each time point,
were recorded from the chart review. The time points evaluated were baseline, 3, and 6 months, followed
by every 6 months until last visit available to a maximum follow-up of 72 months. Visual acuity was
converted from Snellen chart to logarithm of the minimum angle of resolution (logMAR) for statistical
analysis. The type of anti-VEGF agent used for each patient was recorded. Surgical events occurring
during the period of the analysis were recorded. The retention rate refers to the proportion of patients who
were not lost to follow-up or switched to another treatment strategy before final data collection. Whenever
possible, the reason for patients dropping out of treatment or the TER was ascertained from the medical
record and/or by contacting the patient directly.
2.2. Injection Technique
All injections were performed under topical anesthesia. Prior to injection, the eye was treated with topical
proparacaine hydrochloride (0.5%) and topical 5% povidone-iodine solution. Injections were performed
3.5–4.0 mm posterior to the limbus with either a 30-gauge or 32-gauge needle (ranibizumab (0.5 mg/0.05
mL) and aflibercept (2.0 mg/0.05 mL)) or a 31-gauge needle (bevacizumab (1.25 mg/0.05 mL)). No
paracenteses or intraocular pressure measurements were performed immediately after injection. All eyes
received 3 monthly (4–6 weeks apart) loading doses and were subsequently managed with a TER as
described previously, in which maintenance therapy was given while attempting to increase the time
interval between treatments [7]. The maximum interval between maintenance injections was typically 9
weeks.
2.3. Image Grading
FA images were obtained using a Topcon TRC 50IX fundus camera (Topcon Imagenet, Tokyo, Japan).
OCT imaging of all patients was performed with time-domain OCT (Stratus, Carl Zeiss Meditec Inc.,
Dublin, CA, USA) or spectral-domain OCT (Spectralis, Heidelberg Engineering, Heidelberg, Germany; or
3-D OCT-2000, Topcon, Tokyo, Japan). The OCT data were used for grading of lesion subtype in the
anatomic classification of lesion composition [22]. Standard methods of image acquisition were employed
for all imaging modalities.
The classification of neovascular lesions was made independently by two experienced retina specialists
(Sarah Mrejen and Roberto Gallego-Pinazo) who evaluated the presenting color photographs, FA, and
OCT. First, all the color photographs and FA corresponding to the baseline diagnostic visit were analyzed.
Neovascular lesions were subtyped according to the MPS criteria [20] and the Digital Angiographic
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Reading Center Reader’s Manual as occult or classic CNV, and retinal angiomatous proliferation (RAP)
lesions were identified by criteria defined by Yannuzzi et al. [25] and the Digital Angiographic Reading
Center Reader’s Manual. Secondly, OCT images corresponding to the same diagnostic visit were
reviewed, and each case was classified according to the guidelines provided by Freund et al. [22]. The
anatomic classification, which utilizes OCT in combination with FA, categorizes lesions as Type 1 (sub-
RPE), Type 2 (subretinal), Type 3 (intraretinal), or Type 4 (mixed lesions) neovascularization (NV). Eyes
with polypoidal choroidal vasculopathy (PCV) were considered to be a form of Type 1 NV. Cases with
multiple lesion types were identified as mixed NV and each component was also recorded. The specific
criteria used in the anatomic classification have been previously described [22,23]. Finally, in cases with
disagreement between FA and OCT findings, FA images were re-analyzed paying special attention to the
early frames in order to better recognize subtle angiographic findings, in particular those of Type 3/RAP
lesions that might have not been recognized during the first analysis of the images. A third supervising
grader (K. Bailey Freund) evaluated the lesion type in the presence of significant discrepancies.
Readers also graded the lesion location and overall size. FA was used to measure the greatest linear
dimension (mm) and the total area of CNV lesion (mm²). Measurements were performed only on fundus
camera images. The total area of CNV lesion was defined as the area of CNV leakage plus any contiguous
areas of thick hemorrhage, blocked fluorescence, or serous PED that could be obscuring the boundaries of
the CNV. The lesion location was defined as subfoveal, juxtafoveal, or extrafoveal as determined
according to the MPS terminology [20]. Specifically, foveal location was defined as the most posterior
border of the lesion, including blood or blocked fluorescence involving the geometrical center of the fovea
as observed on FA.
2.4. Statistical Analysis
Baseline predictors were measured on a categorical scale (anatomic classification, FA classification, lesion
localization) or on a continuous scale (logMAR VA, lesion area, and number of injections). Since the
duration of follow-up was heterogeneous mainly due to inclusion of patients at different time points
between 2006 and 2011, the analysis was done at each time point and not final follow-up.
We analyzed predictors for 4 VA outcomes, including VA score, change in VA score from baseline, a gain
of ≥3 lines (i.e., 15 letters) from baseline, and a loss of ≤1 line (i.e., 5 letters) from baseline. Bivariate
relationships between the 4 VA outcomes and the various baseline parameters were evaluated without
adjustment for other covariates using the two-sample t-test, Wilcoxon rank sum test, or Spearman’s
correlation for continuous variables, and the chi-square test, Fisher’s exact test, or one way analysis of
variance (ANOVA) for categorical variables. Bivariate analysis was repeated at time points of interest (6
months, 1, 2, 3, 4, 5 and 6 years) in which there was enough statistical power for assessment. To compare
quantitative variables among the different groups for multiple comparisons, one way ANOVA was used
with Games-Howell for unequal variances corrections and with Bonferroni for equal variances corrections.
Bilaterality was evaluated as a parameter in the bivariate analysis, but this does not completely solve the
problem of bilaterality since two eyes from the same patient cannot be considered independent.
Specific clinical characteristics were further assessed for a potential independent effect on the VA
outcomes of interest. The number of subjects in the different outcome groups limited the number of
variables that could be explored in the multivariate model. Based on the bivariate analyses and a priori
considerations, certain variables were not included for further evaluation. Variables that resulted in a p-
value <0.2 from the bivariate analyses at various time points were further evaluated using a generalized
linear model for VA and change in VA from baseline. An assessment of collinearity between predictors
was performed prior to the specification of the final multivariate model. All p-values were two-sided with
statistical significance at the 0.05 alpha level. Beta (β) and standard error (SE) were constructed to assess
the precision of the obtained estimates. All data were analyzed in SPSS Version 22 (SPSS Inc., Chicago,
IL, USA).
3. Results
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3. Results
A total of 374 patients initiated anti-VEGF therapy for newly diagnosed treatment-naïve neovascular
AMD between 1 January, 2006 and 1 December 2011. Among these 374 patients, 185 patients (210 eyes)
met the eligibility criteria.
3.1. Baseline Demographic Characteristics and Correlation with Visual Outcome
Among the 185 patients, the mean age ±SD at first injection was 81.1 ± 8.0 years; 13.5% of patients
(25/185) had bilateral study-eligible disease; 67.6% (125/185) were women; 95.1% (176/185) were white,
followed by Hispanic 2.2% (4/185), Asian 2.2% (4/185), and Black 0.5% (1/185). Among the 185 patients,
70.8% (131/185) had no history of smoking, 23.8% (44/185) were former smokers and 5.4% (10/185)
current smokers. There was a family history of AMD in 18.9% of cases (35/185), a history of hypertension
in 61.1% (113/185), diabetes in 10.8% (20/185); 37.3% (69/185) were using statin medication, 35.7%
(66/185) aspirin, 5.9% (11/185) clopidogrel, and 8.6% (16/185) warfarin. There was a history of glaucoma
in 8.6% (16/185) of patients.
The correlations between baseline demographic characteristics and visual outcomes were evaluated at all
time points (details not shown). The bivariate analysis revealed that an older age at first injection was
correlated with poorer visual acuity at 1, 2, 3 and 4 years. Hypertension was correlated with poorer visual
outcome at baseline, 1, 2 and 5 years. Aspirin intake was correlated with poorer visual acuity at 1 year and
6 years. Clopidogrel intake was correlated with poorer visual acuity at 6 years. There was no significant
correlation with any of the demographic variables and visual change at any time point (data not shown).
Bilaterality was evaluated as a parameter in the bivariate analysis and was not significantly associated with
VA or change in VA at any time point evaluated.
3.2. Neovascular Lesions and Number of Injections
The distribution of neovascular lesion subtypes according to anatomic classification was: 38.6% of Type 1
NV, 8.6% of Type 2 NV, 34.3% of Type 3 NV and 18.6% of Type 4 (mixed lesions) NV. Patients received
a mean of 28.5 ± 14.3 injections over a mean follow-up period of 3.5 ± 1.67 years. The mean number of
injections per year was 8.3 ± 1.6 (range 4 to 13) and the mean interval between injections was 6.6 ± 1.5
weeks. The mean number of injections per year was 8.8, 7.7, 8.1, and 7.8 for Type 1, 2, 3 and 4 NV
respectively. The mean number of injections according to lesion composition is detailed in Table 2. The
neovascular lesion localization was foveal in 63% (133/210), juxtafoveal in 18% (37/210), and extrafoveal
in 19% (40/210) of eyes. The mean overall lesion area was 6.6 ± 5.9 mm² and the mean greatest lesion
diameter 3.2 ± 1.5 mm. The majority, 59% (124/210), received ranibizumab only treatment, and the
remainder received either a combination of ranibizumab and aflibercept 15.7% (33/210), ranibizumab and
bevacizumab 14.3% (30/210), all three agents 5.7% (12/210), bevacizumab alone 4.3% (9/210) or
aflibercept alone 1% (2/210). Thirty out of 210 eyes (14.3%) had cataract extraction over the 6 year time
period.
3.3. Retention Rate
The retention rate for the entire cohort was 62.9% over the 6 year time period (132/210 eyes). The reasons
for the 78 eyes falling out of the TER were as follows: death (20), transferred care elsewhere due to
relocation (20), switched to PRN strategy at the treating physician’s discretion due to risk of progressive
geographic atrophy (14) and missed or delayed appointment due to unrelated systemic illness (7). Only 17
of 210 eyes (8.1%) were lost to follow-up for unknown reason. The retention rate was 100% (210/210) at 1
year, 83% (174/210) at 2 years, 61% (128/210) at 3 years, 42% (88/210) at 4 years, 26% (54/210) at 5
years and 13% (27/210) at 6 years.
3.4. Visual Results for the Entire Cohort
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The results of mean visual acuity for the entire cohort are detailed in Figure 1. Visual benefits obtained at 6
months were largely maintained long-term at 3, 4, and 6 years, although, at 5 years, there was a decline in
mean VA approaching baseline VA, which appears inconsistent with the rest of the curve. For the entire
cohort, the mean visual changes from baseline are detailed in Figure 2. Maximal visual benefits from
baseline were seen at 18 months (−0.1245 logMAR, equivalent of 1.245 lines). Despite a slight decrease
long term, these visual benefits were maintained with a visual gain of −0.1061, −0.0896, and −0.0782
logMAR at 3, 4, and 5 years respectively. At 6 years, one isolated point shows a mean visual gain of
−0.1626 logMAR, not consistent with the rest of the curve (Figure 2). This may be due to a relatively
smaller number of patients with very long follow-up, or a biased retention of patients with better visual
outcome.
For the entire cohort, the significant clinical predictors of visual acuity at all time points in bivariate
analysis were baseline VA, 6 month VA, number of injections, and anatomic classification (Table 1 and 
Table 3). Baseline and 6 month VA were positively correlated with VA at all time points (6, 12, 24, 36, 48,
60, and 72 months). The fluorescein classification was not correlated with visual acuity at any time point.
Using the anatomic classification, eyes with Type 1 NV had significantly better visual acuity than other
neovascular subtypes at all time points. The predictors of visual change at all time points were baseline VA
and number of injections in bivariate analysis (Table 1 and Table 3). Baseline VA was negatively
correlated with visual acuity change at all time points (6, 12, 24, 36, 48, 60, and 72 months).
Patients with worse baseline VA were more likely to improve over time. Overall lesion area was
significantly negatively correlated with visual change at 1 year (p = 0.012) and 4 years (p = 0.043, Table 3
). Smaller lesions were more likely to improve in VA. The anatomic classification was correlated with
visual change at 1 year (p = 0.058, Table 1) and 3 years (p = 0.001). The fluorescein classification was
correlated with visual change at 1 year (p = 0.006, Table 1). Eyes with Type 2 NV had greater visual
improvement compared to other neovascular subtypes at 1, 2, and 3 years. At 4 years, eyes with Type 1
NV had greater visual improvement compared to other subtypes. We used independent sample t-tests of
visual acuity at each time point versus presence or absence of a cataract operation before that time point
during the study period, and there was no significant association between cataract extraction and visual
acuity at any time point.
Post hoc adjustments for multiple comparisons revealed a statistically significant difference in anatomic
classification between Type 1 and Type 4 (mixed lesions) with visual acuity at 1 year (p < 0.001), 2 years
(p = 0.002), 3 years (p < 0.001), and 4 years (p = 0.003) (Table 1 and Table 3). No significant differences
were noted among the other pairwise comparisons of anatomic classifications (1 vs. 2; 1 vs. 3; 2 vs. 3; 3 vs.
4). Post hoc adjustments for multiple comparisons revealed a statistically significant difference in
fluorescein classification when comparing changes in VA at 1 year from baseline between groups 1 vs. 2 (p
= 0.023); and 2 vs. 3 (p = 0.004) (Table 1). No significant differences were noted among the other pairwise
comparisons of fluorescein classification at other time points.
3.5. Visual Results by Neovascular Phenotype
The visual results over time by neovascular lesion type are detailed in Figure 3 and Table 1 and Table 3.
Eyes with Type 1 NV started with better baseline VA, followed by Types 3, 2, and 4 (mixed) NV and this
sequence remained true at 1, 2, 3 and 4 years (Figure 3). The visual results by neovascular lesion type at 5
and 6 years are not detailed due to smaller number of patients in each subgroup. The fluctuations of the
curve representing visual acuity of patients with Type 2 NV on Figure 3 may be due to smaller number of
patients with that neovascular lesion subtype. Figure 4 shows the mean visual change by neovascular
lesion type using the anatomic classification. Visual change increased in all subtypes between baseline and
1 year and then decreased slightly in all subtypes except for eyes with Type 1 NV that continued to show
visual improvement until 4 years (Figure 4).
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3.6. Multivariate Analysis
The results of multivariate analysis are detailed in Table 4 for the entire cohort, and for the subgroup of
patients with at least 4 years of follow-up (88 eyes) in Table 5. The anatomic classification was included in
the multivariate analysis and not the fluorescein classification because the anatomic classification was
more consistently and strongly correlated with visual acuity and visual changes over time in the bivariate
analysis. For the entire cohort (Table 4), the number of injections and anatomic classification were
consistently and independently correlated with visual acuity at all time points. The number of injections
was the strongest independent predictor of visual acuity at all time points. Eyes with Type 1 NV had better
visual outcomes compared to the other neovascular phenotypes. The number of injections was also an
independent predictor of visual improvement at 6 months (p = 0.054) and 1 year (p = 0.033). Overall
lesion area was an independent predictor of visual acuity at 1 (p = 0.019), 2 (p = 0.003), and 3 years (p =
0.049). Smaller lesions were more likely to have better visual acuity. Lesion localization was an
independent predictor of visual change at 1 (p = 0.044), 2 (p = 0.045), and 3 years (p = 0.007). Subfoveal
neovascular lesions were more likely to show visual improvement compared to extrafoveal lesions. For the
subgroup of patients with at least 4 years of follow-up, the results were similar to the entire cohort (Table 5
) The anatomic classification and number of injections were again independent predictors of visual acuity
at all time points in the multivariate analysis. However, overall lesion area and lesion localization were not
significant independent predictors of visual acuity or visual acuity change.
3.7. Intraocular Pressure and Safety
The mean intraocular pressure (IOP) at baseline was 14.4 ± 2.8 mm Hg. There were no IOP elevations
greater than 31 mm Hg recorded at any of the study time points and no eyes with sustained IOP elevations
above 25 mm Hg. There were no injection-related complications such as endophthalmitis and retinal
detachment. No serious systemic adverse events were recorded in the charts.
4. Discussion
We present one of the largest cohorts of neovascular AMD patients managed with a TER of intravitreal
anti-VEGF therapy. This consecutive series was treated by a single physician (K. Bailey Freund) over a 6
year period during which nearly all eyes with treatment-naive neovascular AMD were managed with a
TER. The mean follow-up of 42 months is longer than that of previous reports on the use of a TER for this
diagnosis. In addition, the retention rate of 62.9% is considerably higher than that of similar long-term
follow-up studies [26,27].
In order to compare our results to those of eyes treated in the large randomized trials of anti-VEGF therapy
for neovascular AMD, we used inclusion criteria similar to those used in ANCHOR, MARINA, and other
large clinical trials exploring intravitreal anti-VEGF therapy for neovascular AMD [3,4,9,10]. However,
unlike some of these trials, we chose to include eyes with all neovascular lesion sub-types including type 3
NV/RAP and PCV (considered as variant of type 1 NV/occult lesions). While PCV lesions were
uncommon in our cohort (3.3% of eyes), type 3 NV/RAP accounted for 34% of the treatment-naive cases
meeting our inclusion criteria. As type 3 NV/RAP eyes had somewhat worse visual outcomes than the
mean VA for all lesion types, their inclusion resulted in worse mean visual acuities at each time point.
Nevertheless, the mean visual change of −0.115 logMAR (equivalent of +1.15 lines) at 2 years in our
cohort was similar to that for eyes in the MARINA and ANCHOR trials at 2 years eyes, which improved
by 7.2 letters and 10.7 letters, respectively. Other VA efficacy endpoints were comparable as well, with
30% achieving 3 line gains (38% for eyes with Type 1 NV) at 2 years, compared to 33.8% and 41% in the
MARINA and ANCHOR trials, respectively [3,4].
The visual benefits achieved at 1 and 2 years were largely maintained with continued therapy after a mean
follow-up of the entire cohort of 3.5 years. In the subgroup of patients followed for 4 (n = 88) and 6 years
(n = 27), the visual benefits were maintained as well, but these results will need to be confirmed in larger
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series of patients managed with a TER. As the follow-up extended toward 5 to 6 years, there were fewer
eyes available for analysis likely leading to fluctuation in overall visual acuity and in the standard
deviations at each time point (Figure 1), but the overall trend demonstrated an initial improvement similar
to the other major treatment studies with general trend toward stabilization with minimal loss. Whereas
patients in the MARINA and ANCHOR trials were examined and treated every 4 weeks, our patients were
examined less often and received injections a mean of every 6.3 weeks (8.3 injections per year).
There is limited data available on long-term follow-up beyond 2 years in patients with neovascular AMD
treated with anti-VEGF, and our results compare favorably to the available published literature. Most
published long-term studies have reported unchanged visual acuity compared with baseline acuity after 3,
4 [27,28], and 7 years [26], and consistently found a gradual visual loss over time from the initial benefits
obtained at 2 years [26,27,28]. The long-term data from HORIZON [27], SECURE [29], and SEVEN-UP
[26] all suggested that the incremental decline of vision over time may be due to underlying disease
progression or decrease in injection frequency over time [26,27]. Each of these open-label extension
studies also had significant loss of patients by 5–6 years that may have also influenced these visual
outcomes. As opposed to the HORIZON study in which the patients were seen every 3 months and treated
at the discretion of the investigator [27], in the open-label extension of the VIEW 1 study, aflibercept
injections were repeated at least every 12 weeks which appears to have helped to maintain visual benefits
of +7.0 letters at 192 weeks in 323 patients, suggesting the possibility of maintaining long-term visual
benefits with continuous anti-VEGF therapy [30]. Recently, Rayess and colleagues [17] followed a cohort
of 212 eyes from 196 patients over 3 years with a TER; and although they also lost a significant proportion
of eyes and only analyzed 27.8% (59/212) eyes at 3 years, they confirmed the possible long-term visual
and anatomical benefits of TER. Our extended follow-up data from a single practitioner utilizing a uniform
TER help confirm the potential to maintain long-term visual gains by maintaining continuous anti-VEGF
therapy and adjusting the interval to treatment response through the TER approach. It is possible that this
strategy results in better long-term visual outcomes compared to PRN regimens by reducing the risk of
complications associated with recurrent neovascular activity such as catastrophic macular hemorrhages. In
addition, continuous therapy might minimize the potential for continued growth and maturation of
neovascular membranes that might lead to subsequent treatment resistance [31], but parameters such as
these were not part of the outcome measures in this analysis.
The number of intravitreal anti-VEGF injections has been consistently positively correlated with visual
outcome in numerous studies including the current analysis [9]. Even though the association between
number of injections and visual outcome has not always been analyzed in long-term studies [27], the
SEVEN-UP study found that, after seven years of follow-up, the subgroup of patients who received more
anti-VEGF injections had significantly better visual gains [26]. However, the number of anti-VEGF
injections has recently been demonstrated to be significantly correlated with the development of GA in
neovascular AMD [9,32]. As a greater number of injections correlates with both better visual outcomes
and a higher rate of GA, an individualized retreatment strategy may be an attractive alternative to
potentially strike a balance between too many and too few injections.
In our analysis of the association between baseline lesion composition and long-term visual outcomes,
eyes with Type 1 NV appeared to do the best and were the only group that maintained long-term visual
gains. Eyes with other lesion subtypes incrementally lost vision after an initial phase of visual
improvement (Figure 3 and Figure 4). Xu et al. [24] evaluated the risk of developing GA in this same
cohort of patients and found that the eyes with Type 1 NV were 6.7 times less likely to develop GA
compared to the other neovascular subtypes. These results suggest that the assessment of the neovascular
lesion subtype may be helpful for an individualized therapeutic strategy. For example, several studies have
found an association between Type 3 NV/RAP lesions and GA development in eyes receiving intravitreal
anti-VEGF therapy [32,33] and in the fellow untreated non-neovascular eye [34]. The sub-analysis of the
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) study demonstrated that the
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presence of a RAP lesion was an independent predictor of developing GA at 2 years [32]. In our analysis,
eyes with Type 3 NV and eyes with Type 4 NV (mixed lesions) that included a Type 3 NV component may
have lost the initial visual benefits obtained at 2 years due to the development of GA or due to central
progression of pre-existing GA (eyes with central GA at baseline were excluded from this analysis). The
sub-analysis of the CATT study assessing the risk of scarring found that eyes with classic CNV were more
likely to develop scarring at 2 years [35]. In this analysis, eyes with Type 2 NV and eyes with Type 4
(mixed lesions) NV including a Type 2 component may have also lost the initial visual benefits due to
scarring. In a histopathological study of AMD eyes with disciform scars, Green reported that 37% had
areolar atrophy associated with the scar, indicating that GA and scarring are not mutually exclusive
complications in neovascular AMD [36].
In our study, eyes with Type 1 NV received more frequent anti-VEGF injections than other NV types,
presumably due to more refractory exudative signs. Despite some refractory subretinal fluid (SRF), eyes
with Type 1 NV had the best visual outcomes and developed less GA than eyes with other lesions
subtypes. A possible explanation for these results may be that sub-RPE NV is a more mature form of NV
with a slower growth potential. In addition, Grossniklaus and Green have hypothesized that sub-RPE NV
is a compensatory form of neovascularization that could provide nutrients and oxygen to the RPE and
outer retina [37]. There may be nutrients in the chronic SRF that help maintain photoreceptor integrity
[38]. Perhaps, for these reasons, eyes with Type 1 NV are more likely to have long-term benefit from long-
term maintenance anti-VEGF therapy with a TER approach than eyes with other lesions. Conversely, eyes
with Type 2, 3, and 4 (mixed) NV may be more prone to develop GA and scarring and be less likely to
maintain long-term visual benefits with long-term anti-VEGF therapy on a TER approach.
In order to individualize therapy based on initial lesion composition, there is a need for an accurate and
reproducible method to assess lesion composition. In this study, the anatomic classification correlated
more closely than the fluorescein classification with visual outcomes at all time points evaluated from
baseline to 4 years (Table 1 and Table 3). The anatomic classification was also an independent predictor of
visual acuity at all time points in the multivariate analysis (Table 4 and Table 5). Based on fluorescein
alone, Cohen and associates showed that there was only moderate inter-grader agreement [39]. Jung and
associates analyzed the data of this cohort using FA alone versus combined FA and OCT and concluded
that the anatomic classification may be a more accurate and reliable way to assess neovascular phenotype
[23]. They also showed that the addition of OCT to FA allowed the two readers to make a more precise
identification of Type 3 NV/RAP and mixed lesions [23]. As mentioned above, the clinical relevance of
the anatomic classification has also been demonstrated in an analysis of this same cohort finding a stronger
correlation between GA progression and neovascular lesion type when using the anatomic classification
compared to FA classification [24]. We report a frequency of Type 3 NV/RAP lesions as high as 34% in
our cohort. It is noteworthy that this neovascular subtype has rarely been analyzed as a separate category in
the major neovascular AMD treatment trials and these eyes may have been included the cohorts of eyes
graded as having occult or minimally classic lesions based on FA grading [4,9]. The main report of the
CATT [9] did not mention RAP lesions but, in the sub-analysis assessing the risk of GA, the entire cohort
has been categorized into predominantly classic, minimally classic, and occult lesions, and the presence of
RAP has been noted as a separate finding [32]. In the CATT report, it is not mentioned exactly how RAP
lesions were diagnosed, whether it was by OCT, FA, or a combination of both [32].
There has been some concern regarding the higher number of injections in a TER approach and subsequent
increased risk of complications. One possibility is an increased risk for sustained IOP elevation with
greater number of injections.[40,41] In this report, there were no IOP elevations greater than 31 mmHg at
all time points and no sustained IOP elevations above 25 mm Hg. There were no cases of endophthalmitis,
retinal detachment, or other serious ocular or systemic adverse events.
We acknowledge that there are inherent limitations of this study including its retrospective nature, the use
of different OCT devices to classify the neovascular lesions and use of different anti-VEGF agents. Some
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limitations were intrinsic to the very long follow-up period up to 6.6 years such as changes in the
treatments available during this period and fewer number of patients at each extended follow-up periods of
5 and 6 years. For example, some patients were first evaluated before the availability of spectral domain
OCT and had time domain OCT at baseline. In addition, patients treated with aflibercept soon after its
commercial approval may have been managed differently due to the impression that this drug may have a
more durable effect. The choice of drug may not have been independent of baseline characteristics. It is
possible that larger lesion size would fail extension and benefit being switched to aflibercept. Therefore,
the choice of drug may have been a confounder for the visual outcome. Moreover, a greater proportion of
eyes enrolled later in the enrollment period may have been treated with aflibercept and have shorter
follow-up. Another limitation was that a small number of eyes were switched to a PRN regimen (6.7%)
due to concerns regarding a theoretical increased risk for the development of or progression of central
geographic atrophy. This subgroup of patients included a disproportionate number of eyes with Type 2, 3
and mixed lesions that may have been at a higher risk for a poorer visual outcome therefore potentially
biasing toward good visual outcomes. The minimum follow-up was only 1 year, which is relatively short
for a long-term analysis, but a separate analysis of the subgroup of patients with at least 4 years of follow-
up (N = 88 eyes) found similar results (Table 5). A small proportion of patients underwent cataract surgery
over the study period, which could affect the visual acuity outcomes, although no statistically significant
association was found between visual acuity and cataract operation. Additionally, there were 13.5%
bilateral cases in which injections were typically given to both eyes on the same day. In these cases, the
eye requiring more frequent injections often dictated the TER interval. Therefore, the treatment interval in
these patients may have been biased to a shorter length. Moreover, eyes from the same patient cannot be
considered independent and a non-significant result in a bivariate analysis does not completely solve this
problem. Therefore including both eyes from some patients remains a weakness of our study. Despite these
limitations, it has been possible to draw a number of statistically sound conclusions that we believe are of
significant value in guiding real-word clinical practice.
In this retrospective study, a TER for eyes with treatment-naive neovascular AMD produced long-term
visual benefits with a mean of 8.3 injections per year. While we acknowledge a potential bias of patients
with better visual outcomes being more likely to remain on the prescribed regimen than those doing
poorly, our retention rate of 62.9% is considerably higher than similar cohorts, possibly indicating that the
TER strategy may actually improve patient compliance by reducing the burden of frequent visits compared
to PRN dosing strategies. Moreover, the reasons why patients fell out of the TER were well documented
for the majority of eyes and was not due to a poor visual prognosis but to death, relocation or unrelated
systemic illness delaying an appointment. There were only 8.1% lost to follow-up for unknown reasons,
likely minimally influencing the long-term visual outcomes.
As eyes with Type 1 NV had better visual outcomes than other neovascular subtypes despite requiring
more frequent injections,, our results suggest that individualizing anti-VEGF therapy based on initial
lesion composition may be of value. The anatomic classification was more strongly correlated with visual
outcome than the fluorescein classification and one of the only 2 independent predictors of visual outcome
at all time points, the other being a higher number of injections.
5. Conclusions
In conclusion, our results presented here and in other published findings from this same patient cohort
[23,24] suggest that an anatomic classification of neovascular lesion composition based on multimodal
imaging AMD may be more clinically meaningful than the fluorescein agiography-based classification and
may be useful in guiding individualized therapeutic dosing strategies including the TER. A TER provided
sustained long-term visual gains with a high patient retention rate. Eyes with Type 1 neovascularization
had better visual outcomes than those with other neovascular lesion subtypes.
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Table 1
Bivariate associations of baseline clinical characteristics and visual parameters at 3 years.
Baseline Characteristics N
= 128 Eyes
VA at 3 Years
(logMAR)
VA Change at 3 Years
(logMAR)
≥3 Line Gainat 3
Years
≥1 Line Lossat
3 Years
Adjusted
Mean (SE)
p
Value
Adjusted Mean
(SE)
p
Value
Number
(%)
p
Value
Number
(%)
p
Value
Baseline Characteristics N
= 128 Eyes
VA at 3 Years
(logMAR)
VA Change at 3 Years
(logMAR)
≥3 Line Gainat 3
Years
≥1 Line Lossat
3 Years
Adjusted
Mean (SE)
p
Value
Adjusted Mean
(SE)
p
Value
Number
(%)
p
Value
Number
(%)
p
Value
Baseline VA - <0.001 - <0.001 - <0.001 - 0.11
6-month VA - <0.001 - 0.068 - 0.979 - 0.083
Total 0.544 (0.037) −0.106 (0.033) 38 (28%)
28
(22%)
Anatomic classification 0.006 0.001 0.041 0.478
1 0.390 (0.050) −0.113 (0.048) 18 (47%) 9 (32%)
2 0.695 (0.129) −0.215 (0.123) 6 (16%) 3 (11%)
3 0.534 (0.055) −0.060 (0.051) 9 (24%) 9 (32%)
4 0.761 (0.096) −0.109 (0.087) 5 (13%) 7 (25%)
Fluorescein classification 0.544 (0.037) 0.214 −0.106 (0.033) 0.194 0.521 0.613
1 0.463 (0.051) −0.076 (0.043) 18 (47%)
13
(46%)
2 0.651 (0.109) −0.269 (0.100) 8 (21%) 3 (11%)
3 0.606 (0.066) −0.068 (0.064) 9 (24%) 8 (29%)
4 0.593 (0.122) −0.094 (0.098) 3 (8%) 4 (14%)
Lesion location 0.841 0.023 0.09 0.01
foveal 0.552 (0.045) −0.166 (0.041) 31 (82%)
14
(50%)
juxta 0.559 (0.082) 0.001 (0.065) 3 (8%) 6 (21%)
extra 0.490 (0.104) 0.048 (0.066) 4 (11%) 8 (29%)
Lesion area - 0.301 - 0.039 - 0.138 - 0.298
Number of injections - <0.001 - 0.022 - 0.259 - 0.104
VA: visual acuity; logMAR: logarithm of the minimum angle of resolution; SE: standard error.
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Table 2
Mean number of injections broken down yearly according to neovascular lesion type.
Neovascular Lesion Type (FA + OCT)
Mean Number of Injections per Year
1st Year 2nd Year 3rd Year 4th Year 5th Year 6th Year
Type 1 9.4 8.2 8.6 8.6 8.5 9.1
Type 2 8.3 6 7.8 7.8 8.1 8.2
Type 3 8.7 8 7.5 8.1 7.8 8.4
Type 4 (mixed) 8.8 7.3 7.4 6.8 7.9 7
FA: fluorescein angiography; OCT: optical coherence tomography.
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Figure 1
Mean visual acuity over time. The visual acuity is noted in logMAR and Snellen chart, as well as the number of eyes at
each time point.
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Figure 2
Mean visual change from baseline over time. The mean change in visual acuity from baseline is noted in logMAR and
equivalent of lines.
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Table 3
Bivariate associations of baseline clinical variables and visual parameters at 4 years.
Baseline Characteristics N
= 88 Eyes
VA at 4 Years
(logMAR)
VA Change at 4 Years
(logMAR)
≥3 Line Gain at 4
Years
≥1 Line Loss at 4
Years
Adjusted
Mean (SE)
p
Value
Adjusted Mean
(SE)
p
Value
Number
(%)
p
Value
Number
(%)
p
Value
Baseline Characteristics N
= 88 Eyes
VA at 4 Years
(logMAR)
VA Change at 4 Years
(logMAR)
≥3 Line Gain at 4
Years
≥1 Line Loss at 4
Years
Adjusted
Mean (SE)
p
Value
Adjusted Mean
(SE)
p
Value
Number
(%)
p
Value
Number
(%)
p
Value
Baseline VA - <0.001 - 0.002 - 0.001 - 0.384
6 month VA - <0.001 - 0.092 - 0.661 - 0.169
Total 0.574 (0.051) −0.090 (0.044) 26 (30%) 20 (23%)
Anatomic classification 0.006 0.652 0.498 0.314
1 0.354 (0.054) −0.140 (0.054) 11 (42%) 5 (25%)
2 0.773 (0.185) −0.105 (0.138) 3 (12%) 2 (10%)
3 0.599 (0.074) −0.006 (0.073) 7 (27%) 9 (45%)
4 0.826 (0.148) −0.114 (0.137) 5 (19%) 4 (20%)
Fluorescein classification 0.573 (0.051) 0.135 −0.090 (0.044) 0.839 0.002 0.831
1 0.442 (0.061) −0.094 (0.048) 10 (39%) 9 (45%)
2 0.713 (0.176) −0.194 (0.166) 6 (23%) 3 (15%)
3 0.680 (0.089) −0.022 (0.096) 9 (35%) 7 (35%)
4 0.650 (0.178) −0.085 (0.107) 1 (4%) 1 (5%)
Lesion location 0.616 0.25 0.073 0.511
foveal 0.581 (0.061) −0.136 (0.056) 23 (89%) 13 (65%)
juxta 0.636 (0.133) 0.022 (0.072) 1 (4%) 4 (20%)
extra 0.449 (0.139) 0.036 (0.081) 2 (8%) 3 (15%)
Lesion area - 0.592 - 0.043 - 0.049 - 0.085
Number of injections - 0.007 - 0.175 - 0.57 - 0.242
VA: visual acuity; logMAR: logarithm of the minimum angle of resolution; SE: standard error.
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Figure 3
Mean visual acuity in logMAR by neovascular subtype using the anatomic classification. The number of eyes for each
neovascular subtype is reported at each time point.
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Figure 4
Mean visual change from baseline in line equivalent by neovascular subtype using the anatomic classification.
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Table 4
Multivariate analysis of visual acuity and visual acuity change using baseline clinical parameters over
time.
Time
Point
Visual
Parameter
Anatomic
Classification
Number of
Injections
CNV
Localization
Overall Lesion
Area
Age at First
Injection
Time
Point
Visual
Parameter
Anatomic
Classification
Number of
Injections
CNV
Localization
Overall Lesion
Area
Age at First
Injection
6
months
VA
B 0.06 −0.05 −0.04 0.01 0.01
SE 0.03 0.02 0.04 0.01 0.00
p 0.02 0.00 0.26 0.09 0.05
VA Change
B −0.01 −0.03 0.05 −0.01 0.00
SE 0.02 0.01 0.03 0.00 0.00
p 0.55 0.05 0.12 0.15 0.55
12
months
VA
B 0.07 −0.06 −0.03 0.01 0.01
SE 0.03 0.02 0.04 0.01 0.00
p 0.01 0.00 0.50 0.02 0.06
VA Change
B −0.01 −0.03 0.06 0.00 0.00
SE 0.02 0.02 0.03 0.00 0.00
p 0.79 0.03 0.04 0.67 0.58
24
months
VA
B 0.06 −0.07 −0.02 0.02 0.01
SE 0.03 0.02 0.05 0.01 0.00
p 0.04 0.00 0.71 0.00 0.07
VA Change
B −0.01 −0.03 0.08 0.01 0.00
SE 0.02 0.02 0.04 0.01 0.00
p 0.82 0.06 0.05 0.34 0.26
36
months
VA
B 0.09 −0.09 0.02 0.01 -
SE 0.03 0.02 0.05 0.01 -
p 0.00 <0.001 0.65 0.05 -
VA Change
B 0.02 −0.03 0.13 0.00 -
SE 0.03 0.02 0.05 0.01 -
p 0.47 0.11 0.01 0.90 -
48
months
VA
B 0.11 −0.11 0.01 0.00 -
SE 0.04 0.03 0.07 0.01 -
p 0.01 0.00 0.87 0.89 -
VA Change
B 0.02 −0.05 0.10 −0.01 -
SE 0.04 0.03 0.07 0.01 -
p 0.66 0.09 0.15 0.13 -
CNV: choroidal neovascularization; VA: visual acuity; B: beta coefficient; SE: standard error; p: p-value.
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Table 5
Multivariate analysis of visual acuity and visual acuity change using baseline clinical parameters over time
using patients with at least 4 years of follow up (N = 88).
p Values
Time
Point
Visual
Parameter
Anatomic
Classification
Number of
Injections
CNV
Localization
Overall Lesion
Area
Age at First
Injection
6 months
VA 0.043 0.016 0.812 0.564 0.496
VA Change 0.674 0.445 0.056 0.291 0.492
12
months
VA 0.048 0.050 0.859 0.627 0.294
VA Change 0.591 0.856 0.086 0.277 0.286
24
months
VA 0.024 0.026 0.976 0.609 0.193
VA Change 0.367 0.455 0.110 0.294 0.202
36
months
VA 0.021 0.010 0.504 0.769 -
VA Change 0.874 0.271 0.020 0.211 -
48
months
VA 0.011 0.002 0.871 0.887 -
VA Change 0.661 0.090 0.151 0.127 -
CNV: choroidal neovascularization; VA: visual acuity.
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